Written and maintained by CASRAI Editorial Board
Last updated
The Accelerating Medicines Partnership (AMP) is a public-private partnership that links the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), pharmaceutical companies and nonprofit organizations. Its programs are managed through the Foundation for the National Institutes of Health (FNIH) and focus on shared genetic, genomic and clinical data for specific diseases. This guide explains who is involved, how the programs are funded, and how data is stewarded and shared.
For the wider regulatory setting, see regulatory affairs in the pharmaceutical industry and clinical trial protocol design.
What it is and who runs it
Published descriptions of AMP name the following participants (sources and check date are listed at the end of this page):
- NIH: AMP-AD is described as linking NIH, the FDA, pharmaceutical companies and nonprofit organizations. For AMP T2D, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided awards.
- FNIH: The programs are managed through the Foundation for the National Institutes of Health.
- FDA: Named as a partner in AMP-AD.
- Industry and nonprofits: Pharmaceutical companies and nonprofit organizations take part; for AMP SCZ the named funders include the National Institute of Mental Health (NIMH) and Wellcome.
AMP T2D, launched in 2014, was one of three original AMP programs. In 2021 it transitioned to a new partnership, AMP Common Metabolic Diseases (AMP CMD). Other programs include AMP Alzheimer’s Disease (AMP-AD) and AMP Schizophrenia (AMP SCZ).
What it funds or requires
AMP T2D illustrates the dual NIH and FNIH funding model: its consortium funding consisted of 11 NIDDK awards and 21 FNIH awards, providing funding to more than 30 academic institutes. Check each program’s own pages for current funding opportunities and terms.
AMP SCZ describes its grantees as stewards rather than owners of important data sets, and follows the FAIR Guiding Principles (Findable, Accessible, Interoperable, Reusable) for data management. It describes a public data release through the NIMH Data Archive every six months, plus a consortium-only collaboration space for recent data, and uses controlled mechanisms for sensitive data sharing.
How the programs relate
| Program | What the sources state |
|---|---|
| AMP T2D / AMP CMD | AMP T2D launched in 2014 as one of three original AMP programs; it transitioned to AMP CMD in 2021. |
| AMP-AD | Links NIH, the FDA, pharmaceutical companies and nonprofit organizations; works in close collaboration with the Target Enablement to Accelerate Therapy in AD (TREAT-AD) Consortium. |
| AMP SCZ | A public-private partnership managed by the FNIH, with NIMH and Wellcome as named funders; funding started in September 2020. |
For the industry side of translational research, see the pharmaceutical CRO industry sector overview, the placebo-controlled study design entry, and ICH E6 vs ICH E8.
FAQ
What is the Accelerating Medicines Partnership?
A public-private partnership among the NIH, the FDA, pharmaceutical companies and nonprofit organizations, with programs managed through the FNIH.
Who manages AMP?
The Foundation for the National Institutes of Health (FNIH) manages the programs.
How is AMP funded?
AMP T2D is an example: it combined 11 NIDDK awards with 21 FNIH awards across more than 30 academic institutes.
Which diseases do AMP programs cover?
The sources reviewed here describe programs in type 2 diabetes and common metabolic diseases, Alzheimer’s disease and schizophrenia. The official NIH and FNIH program pages list the current set.
How is AMP data shared?
It varies by program. AMP SCZ, for example, releases data publicly through the NIMH Data Archive every six months and uses controlled mechanisms for sensitive data.
Sources
All sources checked 2026-11-07.
- NIDDK and consortium partners. Accelerating Medicines Partnership in Type 2 Diabetes and Common Metabolic Diseases: Collaborating to Maximize the Value of Genetic and Genomic Data. Diabetes, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12185966/
- Lessons from Ten Years of Validation of Targets Identified by the Accelerating Medicines Partnership in Alzheimer’s Disease (AMP-AD). Alzheimer’s and Dementia, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11710593/
- Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership Schizophrenia Program. Schizophrenia, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11968805/
- National Institutes of Health. Accelerating Medicines Partnership (AMP) program page. https://www.nih.gov/research-training/accelerating-medicines-partnership-amp
